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A B S T R A C T
Ionic liquids are a diverse range of charged chemicals with low volatility and often liquids at ambient tem-
peratures. This characteristic has in part lead to them being considered environmentally-friendly replacements for
existing volatile solvents. However, methylimidazolium ionic liquids are slow to break down in the environment
and a recent study at Newcastle detected 1 octyl 3 methylimidazolium (M8OI) – an 8 carbon variant methyli-
midazolium ionic liquid - in soils in close proximity to a landﬁll site. The current M8OI toxicity database in
cultured mammalian cells, in experimental animal studies and in model indicators of environmental impact are
reviewed. Selected analytical data from the Newcastle study suggest the soils in close proximity to the landﬁll
site, an urban soil lacking overt contamination, had variable levels of M8OI. The potential for M8OI - or a
structurally related ionic liquid – to trigger primary biliary cholangitis (PBC), an autoimmune liver disease
thought to be triggered by an unknown agent(s) in the environment, is reviewed.
1. Introduction
Ionic liquids (also frequently referred to as ionic solvents) are salts -
normally composed of organic cations and inorganic anions - with a
melting temperature below 100 °C and often, they are liquids at am-
bient temperatures (Wilkes, 2002). Given their relative low volatility,
they have been proposed as environmentally-friendly solvents (Wilkes,
2002).
The modern era of ionic liquid development started with the gen-
eration of 1-butylpyridinium chloride–aluminium chloride mixtures in
the 1970s (Gale et al., 1978; Wilkes, 2002; Welton, 2018). However,
they are man-made chemicals that do not exist naturally in biological
systems and as a consequence, resist degradation in the environment.
Ionic liquids may currently ﬁnd use in plant protection products e.g.
herbicidal phenoxyacid derivatives. (Pernak et al., 2016). They may
also be used in chemical syntheses, biotechnology and chemical en-
gineering - in applications such as cellulose processing, as lubricants,
corrosion inhibitors and battery electrolytes, for water puriﬁcation,
chemical separation and extraction and biofuel production (Oskarsson
and Wright, 2019).
The ionic liquid 1-octyl-3-methylimidazolium (M8OI, also referred
to as C8[mim]) was recently found at high levels in soils in close
proximity to a landﬁll waste site in the North East of England, and to
have the potential to trigger an auto-immune liver disease primary
biliary cholangitis (PBC) (Probert et al., 2018). M8OI is an 1-alkyl-3-
methyl imidazolium ionic liquid, one of the four major chemical classes
of ionic liquids that also includes N-alkyl-pyridinium, tetraalkyl-am-
monium and tetraalkyl phosphonium liquids (Mallakpour and Dinari,
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T
2012). This article reviews the current state of knowledge regarding the
toxic eﬀects of M8OI in mammalian and environmental models and
their potential to trigger PBC.
2. The toxicology database for M8OI
There are a limited number of studies examining the toxicity of
M8OI. Given that toxicity of the cation may be inﬂuenced by its anion,
the salt used in the studies is identiﬁed.
2.2. Signalling pathway interactions
A number of bioassays have been performed on M8OI (Cl-salt) and
are freely available (https://pubchem.ncbi.nlm.nih.gov/compound/
2734223), populated from the Toxicology in the 21st Century
(Tox21) program. These data indicate that M8OI interacts with the
human sonic hedgehog signaling (Shh); androgen receptor; estrogen
receptor alpha; estrogen related receptor; pregnane X receptor and re-
tinoid-related orphan receptor gamma signalling pathways. M8OI is
also reported to be a disruptor of mitochondrial membrane potential
and to be cytotoxic.
2.3. In vitro (mammalian) studies
M8OI (as the Cl− salt) was shown to increase oxidative stress and
induce the apoptosis of a human hepatocarcinoma cell line (QGY-7701)
by Jing et al. (2013), with an EC50 of approximately 360 μM M8IO (as
the Br− salt) was also reported to be cytotoxic to the human hepatoma
HepG2 cell line but, in agreement with our observations (unpublished),
high concentrations - EC50 of 439.46 μM after 24 h exposure – were
required (Li et al., 2015). An examination of a variety of toxic endpoints
suggested that an induction of reactive oxygen species was an early
eﬀect of exposure and that the mode of cell death was apoptotic based
on induction of caspase activities (Li et al., 2015).
Liu et al. (2016) showed that imidazolium-based ionic liquids (as
the Cl− salts) intercalate with DNA isolated from calf thymus, with
ionic chain length giving rise to increasing binding strength. Thus,
M8OI was shown to be relatively weak at quenching the ﬂuorescence of
an ethidium bromide-DNA complex at 666 μM (<10%) whereas a re-
lated ionic liquid in which the octyl chain was replaced with a 16
carbon chain at this concentration resulted in> 80% ﬂuorescence
quenching.
Ma and Li (2018) further investigated the eﬀects of M8OI (as the
Br− salt) in HepG2 cells and demonstrated that exposure resulted in
changes in heat shock protein 70 and heat shock protein 90 expression
and generally inhibited the total anti-oxidative capacity of the cells.
There was increased phosphorylation of p53, mitochondrial membrane
disruption, cyclooxygenase-2 activation, Bcl-2 family protein modula-
tion, cytochrome c and Smac/DIABLO release and inhibition of apop-
tosis inhibitory protein-2 (c-IAP2) and survivin. The mitochondrial ef-
fects and toxicity were partly inhibited by N-acetyl-cysteine.
The liver progenitor B-13 cell line (Probert et al., 2015) was ob-
served to be markedly sensitive to the Cl− salt of M8OI (EC50 for MTT
reduction ~ 50 μM) and at least 10-fold more sensitive than the he-
patocyte-like (B-13/H) cells derived from them (Probert et al., 2018).
The earliest eﬀect (within minutes) observed after exposure to M8OI
was an inhibition of oxygen consumption in both B-13 and B-13/H
cells. This resulted in AMPK phosphorylation and enhanced glucose
consumption. Replacing glucose with galactose also sensitized cells to
M8OI. Around the time of glucose depletion, the cells underwent
apoptosis as evidenced by an induction of caspase 3/7 activity and
nucleosomal DNA cleavage.
These data suggest that an interaction of M8OI with mitochondria is
likely a key initiating event in the adverse outcome pathway for M8OI
toxicity.
2.4. Published in vivo (Mammalian) studies
Only one study has been published, to our knowledge, in a mam-
malian species in vivo. The acute toxic eﬀects of 1-methyl-3-octylimi-
dazolium bromide [M8IO+ Br−] in mice has been examined. The study
was limited to potential adverse eﬀects up to 24 h after an i.p. ad-
ministration. Ten hours after administration, the authors report histo-
pathological changes in the liver and calculated an LD50 of 35.7 mg/kg
bw (Yu et al., 2008).
In our hands, the target organ for the toxic eﬀects of M8OI (as the
Cl-salt) after i. p. injection was seen to be the kidney based on increases
in serum creatinine, urinary protein, urinary kidney injury molecule 1
(Kim1) and histopathological alterations. These eﬀects were clearly
evident at doses of 10 mg/kg bw per day (dosed twice over a 24 h
period). Eﬀects on the liver at this dose were restricted to depletions of
glycogen and portal tract changes in the absence of any overt histo-
pathological changes associated with tissue injury (Leitch et al.,
manuscript in submission). Given that the proposed mechanism by
which M8OI interacts with cells is via an inhibition of oxidative phos-
phorylation in mitochondria, the kidney may be sensitive to M8OI
through its reliance on cellular respiration for reabsorption. Although
constituting around 0.5% of body mass, kidneys consume 10% of the
oxygen used in cellular respiration (Berg et al., 2002). The kidney may
also likely be the primary route for elimination of systemic M8OI and
therefore be exposed to high intracellular concentrations of M8OI.
2.5. Published studies with model indicators of environmental impact
M8OI [as the Br− salt] has been shown to be acutely toxic to frogs
(R. nigromaculata) during early embryonic development, with the
median lethal concentration values at the early cleavage, early gastrula
and neural plate stages of development being 85.1, 43.4, and 42.4 mg/L
respectively after 96 h exposure (equivalent to 309, 158 and 154 μM
respectively) (Li et al., 2009).
M8OI (as the Cl− salt) reduced MTT reduction activity and re-
plication in E. coli (DH5a) suspension cultures that was associated with
increased cell membrane permeability, with signiﬁcant eﬀects seen at
the lowest concentration examined of 100 μM (Jing et al., 2014).
M8OI (as the hexaﬂuorophosphate salt) was shown to irreversibly
inhibit the germination of wheat seedlings at 4 mg/L (equivalent to
11.8 μM) after 7 days of exposure (Liu et al., 2014). M8OI as either the
Cl− or Br− salts were also toxic, the anion reported by the authors to
have no impact on toxicity (Liu et al., 2016).
Eﬀects on the growth of green algae (S. obliquus) was examined by
Liu et al. (2015) who demonstrated that M8IO and other structurally-
related ionic liquids (as the Cl− salts) aﬀected membrane permeability,
cell morphology and growth (IC50 was determined to be between 0.69
and 0.86 mg/L, equivalent to 3.0–3.7 μM).
Deng et al. (2016) examined the eﬀect of M8OI (as the Br− salt) on
the marine diatom (phytoplankton) S. costatum and demonstrated that
photosynthesis and cell growth were inhibited, the latter with an EC50
of 17.9 and 39.9 mg/L (equivalent to 65 and 145 μM) after 48 and 96 h
exposure respectively.
Zhang et al. (2016) indicated that M8OI (as the Br− salt) was
genotoxic to planarians (ﬂatworms, using D. japonica) through use of a
randomly ampliﬁed polymorphic DNA assay. Using this assay, the au-
thors report evidence of a dose-responsive genotoxicity (4, 7 and 9
changes detected) after 1 day exposure at concentrations of 74, 147 and
220 mg/L respectively (equivalent to 270, 530 and 800 μM).
Nan et al. (2016) exposed ﬁsh (P. dabryanus) to M8OI (as the Cl−
salt). After 48 h there was 20% mortality when ﬁsh were exposed to
126 mg/L and 100% mortality when exposed to 360 mg/L (equivalent
to 550 μM and 1.6 mM respectively). The authors reported that the liver
was a target organ with evidence for oxidative stress DNA damage and
apoptosis presented.
Three types of M8OI (either as the Cl−, Br− or tetraﬂuoroborate)
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were examined for their eﬀects on wheat seedlings (up to 800 mg/kg in
brown soil) over a 13 day period (Xu et al., 2018). All three ionic liquids
inhibited growth (shoot length, root length, pigment content and pro-
line content) of wheat seedlings which was associated with the gen-
eration of reactive oxygen species.
M8OI (as the nitrate) signiﬁcantly reduced the microbial popula-
tions (bacteria, fungi and actinomycetes) and diversity at 10.0 mg/kg in
brown soil on days 10, 20, 30, and 40 (Zhang et al., 2018).
Silver carp (Hypophthalmichthys molitrix) were exposed for 60 days
to M8OI (as the Br−) at concentrations of 1.09 or 4.38 mg/L (Ma et al.,
2018). According to the authors, an elevation in a variety of serum
markers and biochemical assays indicated ﬁsh organ damage and al-
terations in brain, gill, intestine, kidney, liver and muscle enzymes
suggestive of oxidative stress. Some changes in xenobiotic metabolising
enzymes activities (erythromycin-N-demethylase and glutathione S-
transferases); increases in inﬂammatory markers (iNOS, IL-1β, TNF-α
and NF-κB), altered levels of TGF-β and apoptosis markers were re-
ported in liver. An additional report focussed on eﬀects in the spleen
(Ma et al., 2019).
The eﬀect of M8OI (as either the nitrate or Cl−) on marine diatom
Phaeodactylum tricornutum growth was examined and was shown to
be inhibitory, with 96-h EC50 values of 24.0 and 33.6 mg/L respectively
(Chen et al., 2019). Photosynthesis was considered by the authors to
have been inhibited based on signiﬁcant decreases of chlorophyll a and
damage to PSII reaction centres. Content of soluble protein superoxide
dismutase and catalase initially increased signiﬁcantly, likely as an
adaptive response prior to decreases in the cultures with higher con-
centrations of ILs (≥20 mg/L).
The current database on the toxic eﬀects of M8OI in mammalian
systems is therefore extremely limited. There is currently only a single
limited report published on the eﬀects of acute M8OI exposure in mice.
In contrast, the number of studies on the eﬀects of M8OI in model in-
dicators of environmental impact are more extensive. These data
overall suggest that if levels accumulate above a variable threshold,
adverse eﬀects may be seen in the environment, experimental animals
and man.
3. Exposure to M8OI
Although M8OI and structurally-related methylimidazolium ionic
liquids have toxic eﬀects in cells in vitro, in mice and in a variety of
model indicators of environmental impact, there is currently no data to
determine whether there is signiﬁcant contamination of the environ-
ment and/or exposure in man to these chemicals.
Interrogation of the UK National Poisons Information Service's
(http://www.npis.org/toxbase.html) TOXBASE, which provides in-
formation on pharmaceuticals, chemicals (agricultural, household and
industrial), plants and animals, suggests that M8OI is not a listed in-
gredient (Prof Allister Vale, National Poisons Information Service UK,
personal communication). M8OI is also not listed as an ingredient in
any pesticide in the UK according to the UK Health and Safety
Executive COPR Database (https://webcommunities.hse.gov.uk/
connect.ti/pesticides/); in any cosmetic in the EU (https://ec.europa.
eu/growth/sectors/cosmetics/cosing_en) or in any household product
in US (https://hpd.nlm.nih.gov/cgi-bin/household/list?tbl=
TblChemicals&alpha=A). However, over 60 methylimidazolium ionic
liquids have been registered with the European Chemicals Agency
(ECHA), several with toxicity dossiers, suggesting they are being used in
the EU such that they do not require to be listed as an ingredient in any
product.
3.1. ECHA database
The ECHA implements the EU's chemicals legislation and is an ex-
tensive source of information on the chemicals manufactured and im-
ported in Europe. In the EU, there is an obligation under the
Classiﬁcation, Labelling and Packaging (CLP) Regulation ((EC) No
1272/2008) that requires manufacturers and importers to submit
classiﬁcation and labelling information for the substances they are
placing on the market. This information is publicly available within the
C&L Inventory held by ECHA (https://echa.europa.eu/regulations/clp/
cl-inventory). Examination of this database indicates that there are
currently 5 diﬀerent M8OI salts pre-registered with ECHA, but since no
data on their toxicity have been submitted, their production level by
any single producer should be less than 100 tonnes/annum (Dr D Bell,
ECHA - personal communication). Interrogating the database for
structurally-related methylimidazolium ionic liquids currently shows
that 31 ethyl, 22 butyl, 4 hexyl and 2 decyl substituted 3-methylimi-
dazolium ionic salts – in addition to the 5 octyl/M8OI liquids – are
listed (see Table 1). Table 1 indicates that a number of shorter chain
variants are registered which suggests that these variants are being used
industrially. However, in several cases, their production levels are
conﬁdential so that there remains uncertainty as to whether there is
signiﬁcant hazard from these chemicals at the current time.
3.2. Discovery of M8OI in the environment
The Newcastle study was primarily set up to determine proof of
concept whether extracts from soil samples may be screened for the
presence of xenobiotics that interact with receptors known to respond
to xenobiotics or are toxic to cells. To maximise the potential value of
the pilot study, samples were taken from an area in the north east of
England that was of potential interest with regard to PBC incidence. The
area contained a landﬁll site and thirteen sites (from allotments, foot-
paths and the roadside verges) surrounding the peri-urban landﬁll site
were sampled (see Fig. 1).
In accordance with Article 6 of EU directive 199/31/EC on the
landﬁll of waste, the site was (and remains) designated as a non-ha-
zardous waste site. As a non-hazardous waste site, it should only be
used for municipal waste, non-hazardous waste of any other origin
which meets the criteria set out on Annex II of the directive and sta-
bilized, non-reactive hazardous waste. The landﬁll site was originally
an abandoned stone quarry that operated from the 1930s to the 1960s.
It has been used as a landﬁll site since the late 1990s. The landﬁll
sampling locations were also adjacent to a disused colliery and asso-
ciated light railway (that operated between 1890 and 1960), re-
mediated in 1990 and converted into public open space. Other land
uses in the area have been semi-rural and residential throughout the
history of the site. Three separate control sites were also sampled for
comparison (from the University farm in rural Northumberland with a
controlled fertiliser regime for the last 130 years and from two gardens
from separate urban areas in the region). Thus, all sample sites (near
landﬁll and control) were from a region that has experienced a long
period of urban growth and industrialisation with particular emphasis
on heavy industries such as steel, ship building and coal mining. These
industries have dwindled in the last 30 years and the area around the
landﬁll is currently classiﬁed as residential and green space
(Generalised Land Use Database – Oﬃce of National Statistics, 2005).
However, the region has been left with a legacy of industrial con-
tamination associated with these industries, speciﬁcally toxic elements
and polyaromatic hydrocarbons (PAHs). The north east of England is
not unusual in having this, and most of the urban areas of the UK share
this legacy (Johnson et al., 2012).
Chemicals present in soil samples were extracted into aqueous,
ethanol and chloroform liquids (for full methodological details, see
Probert et al., 2018). Mammalian cells in culture were initially exposed
to these extracts (up to 1% v/v; chloroform extracts were dried and re-
suspended in an equivalent volume of DMSO) to screen for toxic eﬀects
(e.g. primarily using the MTT screening assay) over several days. There
was no apparent microbial contamination of the treated mammalian
cell cultures leading to toxic eﬀects (e.g. associated with microbial
growth) over the timescale employed, despite the origin of the extracts
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(Probert et al., 2018). Cells were then transfected with promoter-re-
porter gene constructs (up to 0.1% v/v, below levels that caused toxi-
city; chloroform extracts were dried and re-suspended in an equivalent
volume of DMSO) as a screen for the potential presence of chemicals
activating the aryl hydrocarbon receptor (AhR), pregnane X receptor
(PXR), peroxisome proliferator activated receptor alpha (PPARα), es-
trogen receptor (ER) and androgen receptor (AR). This approach was
designed to screen for chemicals capable of activating or inhibiting the
receptors. In addition, established assays for environmental con-
taminants were performed. Elements (As, B, Ba, Cd, Co, Cr, Cu, Pb, Mn,
Hg, Mo, Ni, Se and Zn) were determined in soil directly via aqua regia
digestion by inductively coupled plasma optical emission spectrometry
(ICP-OES). The chloroform extracts were analysed for PAHs by GC-MS
analysis. Pesticide analysis was determined by UPLC® coupled with
Xevo TQ-S (Waters). For full methodological details, see Probert et al.
(2018).
The levels of 14 toxic heavy metals (e.g. lead, see Fig. 2a) were
determined (Probert et al., 2018). As can be seen for lead levels alone,
whilst not signiﬁcantly diﬀerent, mean levels were higher for control
sample sites than those for sites in close proximity to the landﬁll site,
due to one control site with a very high lead concentration. Considering
all 15 toxic elements combined, control sample site mean total levels
were 2.0± 1.70 g toxic elements/kg soil compared to 2.3± 3.47 g
toxic elements/kg soil for sample sites in close proximity to the landﬁll
site. Two of the sample sites and two of the control sites had elevated of
PAHs. Ten individual categories of PAHs (such as pyrene and ﬂuor-
anthene, see Fig. 2b) were examined and mean total PAHs were higher
in control soils (65 ± 54 mg/kg soil) compared to landﬁll soils
(13 ± 19 mg/kg soil). The concentrations of 24 diﬀerent pesticides
was also examined. Only 2 pesticides (e.g. Diuron, see Fig. 2c and
Omethoate) were detected at levels above 1 mg/kg soil. The combined
mean pesticide levels were higher in control soils (total of
3.9± 1.81 mg/kg soil) compared to soils in close proximity to the
landﬁll site (total of 2.0± 1.69 mg/kg soil). Overall, in both control
sites and sites in close proximity to the landﬁll site, contamination with
toxic elements, PAHs and pesticides were within normal ranges of an
urban soil lacking overt contamination.
All soil sample extracts assessed for activation of selected xenobiotic
receptors were initially screened and used at non-toxic levels to reduce
the potential for toxicity masking xenobiotic activity on the receptors.
Cell viability was primarily assessed using MTT reduction (in con-
junction with morphological examination and limited trypan blue dye
exclusion tests) since it is amenable to high throughput screening,
allowing also for multiple replicates and timepoints. MTT is a substrate
for cellular NAD(P)H-dependent oxidoreductase enzymes and its re-
duction provides an estimate of cellular NAD(P)H generation over a
deﬁned incubation period (Berridge and Tan, 1993). MTT reduction
assays are widely used as a proxy for cell viability. In all but two ex-
tracts (aqueous extracts from sampling sites 1 and 2 in close proximity
to the land ﬁll site), there was little evidence for marked reductions in
MTT activity. In any case, a control construct (not containing the xe-
nobiotic receptor enhancer sequences) was transfected with the re-
porter gene construct at a ﬁxed ratio to control for any non-speciﬁc (e.g.
toxic) eﬀects of extracts on cells. Therefore, reporter gene data were
likely solely reﬂective of receptor activation.
Activation of receptors known to be contacted or activated by xe-
nobiotics (AhR, PXR, PPARα, ER, AR) were used to determine the
presence of chemicals activating or inhibiting these receptors. In ad-
dition, induction of the nuclear factor erythroid 2-related factor 2
(Nrf2) was examined, as an indicator of oxidative stress. For all these
bioassays, except Nrf2, there were chemicals with activity present in
both control sites and sites in close proximity to the landﬁll sites (see
Table 2).
The AhR is typically activated by polyaromatic hydrocarbons which
are generally hydrophobic in nature. It could be seen from any one
particular soil sampling site that the activation of the human AhR was
highest in chloroform extracts, followed by ethanol and then aqueous
extracts (Fig. 3a). In contrast, activation of the nuclear factor-like 2
(Nrf2-Keap1) regulatory pathway was not observed (unpublished data).
A number of other reporter gene-based systems were also examined,
including the metallothionein response (Probert et al., 2018) and the
endoplasmic reticulum stress response (unpublished). Overall, based on
receptor-reporter gene expression screening, the only diﬀerence be-
tween control soils and soils in close proximity to the landﬁll site was
the presence in several landﬁll sampling sites of human ERα-activating
chemicals (Meyer et al., 2017a,b; Probert et al., 2018).
Based on studies using the murine ER orthologues (cloned for use in
another project in the laboratory), it was shown that the murine ERβ
variant 2 receptor was “super-activated” by the soil-derived (xeno)es-
trogens (Meyer et al., 2017a, 2017b), in that activation was not in-
hibited by the ER antagonist IC 182780 (although endogenous estrogen
activation was sensitive to antagonism). M8OI was shown to be capable
of this property on the murine receptor however, it did not activate the
human ERβ (in HEK293 cells) (Leitch et al., 2018). The implications of
ERβ super-activation might have on cholestasis in the mouse and its
relevance, if any, in man are currently unknown. However, an agonist
Fig. 1. Approximate location of sampling sites around the landﬁll waste site used in Probert et al (2018). Prevailing wind is westerly/south westerly.
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for the ERβ has been reported to inhibit liver steatosis in mice fed either
a high fat diet or a methionine choline-deﬁcient diet (Ponnusamy et al.,
2017).
A number of other hepatic cell lines and primary cell cultures (e.g.
human liver cholangiocytes) were also examined given its part-focus on
PBC. The B-13 cell line was shown to be particularly-sensitive to che-
micals present in the aqueous extract of 2 of the 13 sampling sites in
close proximity to a landﬁll site (an eﬀect absent from all 3 control
sampling sites), subsequently shown to contain high levels of (see
Fig. 3b), and to be caused by, M8OI (for structure, see Fig. 3c) (Probert
et al., 2018). The B-13 cell line is a rodent pancreatohepatobiliary
progenitor cell line (it expresses several exocrine pancreatic marker
genes in its proliferative B-13 phenotype) that has the unusual property
of diﬀerentiating into hepatocytes (B-13/H cells) and potentially cho-
langiocytes (bile duct epithelial cells) in response to a relatively simple
hormonal stimulus (Wallace et al., 2010; Wallace et al., 2011, for re-
view of B-13 cells see Probert et al., 2015). It was subsequently shown
that M8OI targets the mitochondria in B-13 and human cholangiocytes,
resulting in an inhibition of oxidative phosphorylation and loss of ATP
levels (Probert et al., 2018). The B-13 cells primarily underwent
Fig. 2. Concentrations of one toxic element
(lead), two PAHs (pyrene + ﬂuoanthene)
and one pesticide (diuron) around a landﬁll
waste site and control sites. Soil samples were
processed as outlined (Probert et al., 2018). A,
Lead (Pb) levels were determined directly via
aqua regia digestion by ICP-OES; B, pyrene and
ﬂuoranthene levels in chloroform extracts by
GC-MS analysis and C, Diuron levels by UPLC
coupled with Xevo TQ-S as described (Probert
et al., 2018). Sample sites correspond to those
schematically described in Fig. 2. All landﬁll and
all control refer to the mean and SD of all sample
sites in close proximity to the landﬁll site and
control sites respectively.
Table 2
Analytical data and toxicity-related endpoint data from the soil samples studied
as described by Probert et al. (2018).
Control sample sites Sample sites in close
proximity to a landﬁll site
Analytical
Pb 326 ± 396 mg/kg soil 144 ± 105
All screened heavy
metals
2080 ± 3436 mg/kg soil 1830 ± 1626
All screened PAHs 65 ± 54 mg/kg soil 13 ± 9.0
All screened pesticides 3.9±1.81 mg/kg soil 2.0 ± 1.69
Cell-based toxicity-related endpoint
Human AhR activation yes yes
Human PXR activation yes yes
Human PPARα
activation
yes yes
Human ERα activation no yes
Human AR activation low low
Rat liver progenitor
cell toxicity
no yes - selected
A.C. Leitch, et al. Food and Chemical Toxicology 136 (2020) 111069
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apoptosis although this ultimately collapses to a necrotic process with
time in vitro.
4. PBC and M8OI
4.1. PBC
PBC is a liver disease characterised by an inﬂammatory and im-
munoreactive reaction in the portal tract regions of the liver lobule (See
Fig. 4). Pathologically, there may be evidence of biliary hyperplasia
(suggestive of cholestatic injury) that, presumably with progression,
leads to cholangiopathy, loss of intra-hepatic bile ducts and ﬁbrosis
(Hirschﬁeld et al., 2018). In the absence of liver pathology being
available, unexplained repeated elevations of serum alkaline phospha-
tase (ALP) and/or γ-glutamyltransferase (GGT) – suggestive of choles-
tasis - and high titres of anti-mitochondrial antibody (AMA,>1:40) are
considered suﬃciently diagnostic for the disease (Hirschﬁeld et al.,
2018). PBC occurs more commonly in women than men (approx. 10:1)
and most often in post-menopausal women. Although treatments are
available to help manage disease progression, there is currently no cure
Fig. 3. Eﬀects of extraction liquid on AhR
activating activity and concentrations of
M8OI from soils. A, human AhR activation
(XRE-luc reporter gene) activities in HepG2 cells
treated with 0.1% (v/v) of the indicated landﬁll
or control site soil PBS (open bars), ethanol
(grey bars) or chloroform extracts (dark grey
bars), as outlined in Probert et al. (2018). Data
are expressed as fold control vehicles (set arbi-
trarily to 1) and are the mean and SD of 3 se-
parate determinations. 3 methylcholanthrene is
a transcriptional activator of the human AhR
(Harvey et al., 2000). B, Soil PBS extract M8OI
levels, determined and quantiﬁed using non
targeted data independent LC-HR-MS/MS as
outlined in Probert et al. (2018) using authentic
pure M8OI as standard. Landﬁll sample sites 1
and 2 had the highest concentrations of M8OI in
the PBS extract (~13 mM), which suggests soil
concentrations of M8OI in the region of at least
0.3 ppm. C, chemical structure of the M8OI ca-
tion.
A.C. Leitch, et al. Food and Chemical Toxicology 136 (2020) 111069
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for PBC.
The presence of AMA in>95% of patients has driven the conclu-
sion that PBC is an auto-immune disease, with AMA being im-
munoreactive to the lipoylated domains of 2 oxo acid dehydrogenase
enzymes such as the E2 component of the pyruvate dehydrogenase
complex (PDC-E2) (Dyson et al., 2015). AMA-negative PBC is associated
with antibodies to other antigens (Hirschﬁeld et al., 2018). Exposure in
susceptible individuals to a xenobiotic(s) that mimics lipoic acid and is
capable of replacing this factor in lipoylated proteins is one of several
theories proposed as a trigger mechanism for PBC. The source of such a
xenobiotic(s) could be the environment through pollution (e.g. Super-
fund chemicals) and/or associated with anthropogenic activities (e.g.
release of coal-derived chemicals). These proposals are derived in part
from a reported 10-fold increase in PBC incidence when patients ob-
tained drinking water from one particular water reservoir in the Shef-
ﬁeld (UK) region in the 1980s (Triger, 1980); that there is spatial
clustering for PBC incidence in the North East of England (which has
been intensively mined for coal in the past) (Prince et al., 2001) and
that there is an increased prevalence of PBC near Superfund toxic waste
sites in the New York City area (Ala et al., 2006).
It should be noted that lipoic acid is an endogenously-synthesised
antioxidant (Tibullo et al., 2017) and has been shown to protect cells
from the redox active toxins such as arsenic (Samuel et al., 2005) and
other heavy metals (Zou et al., 2015; Yang et al., 2017) as well as drugs
(Sandhya et al., 1995; Kim et al., 2014; El-Sayed et al., 2017) and
chemicals (El-Beshbishy et al., 2014; Aly et al., 2016).
4.2. M8OI is metabolised to a lipoic acid-mimicking product by human
hepatocytes
As described above, AMA is immunoreactive to the lipoylated do-
mains of 2 oxo acid dehydrogenase enzymes such as the E2 component
of the pyruvate dehydrogenase complex (PDC-E2). M8OI bears struc-
tural similarity to lipoic acid and the alkyl chain may also be a target for
omega hydroxylation (as occurs with fatty acids via cytochrome P450
4As (Misra and Reddy, 2014). Such an hydroxylation on M8OI would be
the ﬁrst step in its conversion to a carboxyl containing metabolite that
could render it susceptible to covalent incorporation into 2 oxo acid
dehydrogenase enzymes in place of lipoic acid.
Incubating human hepatocytes with M8OI resulted in its metabo-
lism to both the omega hydroxylated product 1-(8-hydroxyoctyl)-3-
methyl-imidazolium (HO8IM) and further oxidation to the carboxylated
product 1-(7-carboxyheptyl)-3-methyl-1H-imidazol-3-ium (COOH7IM)
although this was variable, depending on the donor (Probert et al.,
2018). Low levels of additional metabolites were also detected that
suggest other minor pathways of metabolism may also occur (Fig. 5).
4.3. Enzymatic incorporation of COOH7IM into PDC-E2 in place of lipoic
acid
Lipoic acid is an endogenously produced sulphur-containing mole-
cule required by 2 keto acid dehydrogenase enzymes for their catalytic
function (Solmonson and DeBerardinis, 2018). Lipoic acid is covalently
conjugated to speciﬁc lysine residues, e.g. K132 and K259 in the human
E2 component of the pyruvate dehydrogenase complex. In mammals,
this occurs indirectly from octanoate via an enzymatic conversion as
outlined (Fig. 6a).
As observed in the E. coli scavenging pathway, lipoic acid – at least
in vitro - may be directly conjugated (in E coli by lipoate ligase LplA)
via its activation by the mitochondrial medium-chain acyl-CoA syn-
thetase (Acsm1). However, since exogenous lipoic acid fails to rescue
defects in cells derived from lipoylsynthase (LIAS)-deﬁcient patients;
Lias-deﬁciency in mice is embryo lethal and there is no substantial
evidence to show that ACSM1 activates lipoic acid in vivo (Solmonson
and DeBerardinis, 2018), this “scavenging pathway” may only be re-
levant for xenobiotics.
Using a recombinant peptide sequence consisting of residues
221–314 of the murine E2 component of PDC (Fig. 6b), the enzymatic
conjugation of lipoic acid via the xenobiotic scavenging pathway in vitro
may be followed, through changes in electrophoretic mobility under
native conditions using recombinant bovine Acsm1 and Lipt1 enzymes
in vitro (Walden et al., 2008). When lipoic acid was replaced by
COOH7IM, similar changes in peptide mobility occurred (Probert et al.,
2018) indicating COOH7IM conjugation to the peptide and potential
conjugation in vivo. Conjugation occurs whether GTP or ATP is used as
the activating co-factor (Fig. 6c).
5. Discussion
Demonstrating links, if any, between chemical exposures and de-
layed adverse eﬀects such as the development of chronic diseases is a
major challenge. This challenge becomes greater when the disease is a
rare disease, which is the case with PBC (prevalence of 35/100 000,
with an annual incidence of 2–3/100 000 in the North east of England
Fig. 4. The pathology of PBC in human liver. Typical (immuno)histo-
pathology seen in normal human liver and in liver from a patient diagnosed
with PBC. Liver tissue was obtained via the Newcastle Biobank (https://www.
ncl.ac.uk/biobanks/) with over-arching ethical approval from the Newcastle &
North Tyneside 1 Research Ethics Committee. Liver tissue was formalin-ﬁxed,
processed and (immuno)stained as indicated essentially as previously outlined
(Probert et al., 2014). Sirius red staining identiﬁes collagenous matrix proteins;
vimentin identiﬁes ﬁbrogenic ﬁbroblasts typically predominant in a cholestatic
liver injury and cytokeratin 19 (CK-19) identiﬁes bile duct epithelial cells
(cholangiocytes), for review, see also Wallace et al. (2008).
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(James et al., 1999; McNally et al., 2014). Although there is a clear
genetic pre-disposition to the likelihood of developing PBC, none of the
genetic variants predisposing to PBC are in themselves abnormal (Mells
et al., 2011; Cordell et al., 2015) and the odds-ratios associated with the
most prominent genetic variants (e.g IL12RB2 with an odds ratio 1.52
[95% CI 1.39–1.67] (Mells et al., 2011) are relatively low. This com-
pares to an odds-ratio for the HLA-B*57:01 polymorphism of 36.62 for
ﬂucloxacillin liver injury (Nicoletti et al., 2019).
Several studies have identiﬁed associations between an environ-
mental factor and PBC incidence (Triger, 1980; Prince et al., 2001; Ala
et al., 2006). However, these kind of studies are unlikely to identify
individual causative factors (be they chemicals or other factors such as
an infection). Eﬀect-directed analysis is a rapidly expanding ﬁeld of
research to identify chemicals in environmental mixtures with toxic
eﬀects, using a combination of bioassays and chemical analysis (Brack
et al., 2019). The study by Probert et al. (2018) represents an eﬀect-
directed analysis with regard to identifying causative agents (or mod-
ulating agents) in environmental samples responsible for chronic dis-
eases. Through identifying factors that could be a hazard for triggering
a disease (whether they be a realistic risk to the general population or
not), we may be able to understand in greater detail the molecular
mechanisms of the disease process from the very point of ﬁrst exposure.
With greater understanding of the disease process, and by consideration
of related factors (e.g. through read-across), we may be able to predict
realistic risks for disease causation. We may also be able to monitor the
natural history of the disease process from start to ﬁnish in animal
models. A major diﬃculty in studying a disease process such as PBC is
that patients are probably identiﬁed many years after the trigger pro-
cess. There may be a signiﬁcant period where the changes that occur in
a PBC patient are uncharacterised. Despite the existence of several
spontaneous animal models of PBC-like disease (Katsumi et al., 2015),
to date, exposure to a chemical alone has not been demonstrated to
trigger a PBC disease-like process.
6. Conclusion
Exposure to M8OI (and potentially a range of structurally-related
ionic liquids) could result in conversion to a carboxylic acid metabolite
in human liver. M8OI may therefore have the potential for replacing
lipoic acid in the E2 component of PDC. Oxidative stress associated with
the parent M8OI molecule may also contribute to a depletion of lipoic
acid and enhance the chances that its carboxylic acid metabolite replace
lipoic acid in lipoylated proteins. Such an outcome – in addition to the
M8OI parent chemical's ability to induce the apoptosis of liver pro-
genitors and cholangiocytes - could lead to presentation of COOH7IM-
modiﬁed PDC-E2 to the immune system and loss of tolerance to PDC-E2
and the presence of AMA. However, whether there is any exposure to
M8OI (and a range of structurally-related ionic liquids) is not known
and presently, it is presumed to be low. Therefore, it remains conjecture
that M8OI (and a range of structurally-related ionic liquids) is any risk
with respect to triggering PBC.
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